A Phase 1, 2-Part, Single Ascending Dose Assessment of the Safety, Tolerability, and Pharmacokinetics of Rolapitant Intravenous in Healthy Volunteers

Completed · Phase 1

Conditions studied: Chemotherapy-induced Nausea and Vomiting

In brief

The purpose of this study is to assess the safety and tolerability of single increasing doses of intravenously administered rolapitant in healthy male and female subjects.

Key facts

Study ID

NCT02382666

Run by

Tesaro, Inc.

People needed

100

Starts

2015-01-01

Expected to finish

2015-08-01

Last updated by the study team

2015-08-25

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

Where it is running

• Parexel — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.